
    
      A total of 1088 subjects were enrolled in the study at 61 sites internationally, outside the
      United States.

      The study assessed acute and late serious adverse events and reports the rate of stroke and
      bleeding events through 2 years. No formal hypothesis were tested for this observational
      post-market study.

      Each patient was followed at study visits at baseline, implant, 1-3 months, 6 months, 12
      months, and 24 months post implant."
    
  